Inizio Ignite

Aptar Enters into Strategic Partnership with PureCycle to Accelerate Integration of Ultra-Pure Recycled Polypropylene into Dispensing Solutions

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.
- Advertisement -

AptarGroup, Inc., a global leader in dispensing, drug delivery and active packaging solutions, announced that it has partnered with PureCycle Technologies, to prepare for the introduction of PureCycle’s Ultra-Pure Recycled Polypropylene (UPRP) into dispensing applications.

PureCycle’s ground-breaking, patented recycling process, developed and licensed by Procter & Gamble, separates color, odor and any other contaminants from plastic waste feedstock to transform it into UPRP resin with virgin-like properties. This process fully closes the loop in the reuse of recycled plastics while making recycled plastics more accessible at scale to companies desiring to use a sustainable, recycled resin.

Over the next three years, Aptar, an expert in transforming resin into products that delight consumers, will collaborate with and provide critical feedback to PureCycle regarding the transformation process of its UPRP. In addition to providing detailed feedback into how the resin performs during the transformation process, Aptar will play an integral role in helping PureCycle prepare for the food grade requirements in Europe.

“We are pleased to partner with PureCycle Technologies to introduce UPRP into our ever-growing portfolio of dispensing systems. Customers are seeking robust solutions when it comes to sustainable packaging, especially in the food and cosmetics markets, and we believe there are many applications for UPRP that will satisfy those unmet needs,” stated Stephan Tanda, President and CEO of Aptar. “This critical partnership further reinforces our commitment to supporting a circular economy where products and materials are reused or recycled and do not become waste.”

Aptar will have access to the UPRP resin and will make recommendations and propose solutions to help its customers achieve their sustainable packaging goals. This partnership further integrates PureCycle across the value chain to identify more opportunities for a circular product life cycle.

“Aptar’s broad technical expertise, deep market knowledge, and operational preeminence in both the US and European markets will help PureCycle further accelerate our expansion into Europe,” said Mike Otworth, CEO of PureCycle Technologies. “This is not only a technical validation of our process, but a commercial validation of our model that plastic waste is valuable and we as a society must act now to make plastics recycling a reality.”

With the Feedstock Evaluation Unit operational, PureCycle is rapidly progressing towards its bond offering with Piper Jaffray to build its first plant in Lawrence County, Ohio. The facility is expected to recycle 119 million pounds of polypropylene, and is expected to produce approximately 100 million pounds of UPRP per year starting in 2021.

The global polypropylene market is valued at more than $80 billion, according to Transparency Market research, and is on track to reach $133.3 billion by 2023. The Association of Plastics Recyclers (APR) has identified 1 billion pounds of recycled polypropylene demand in North America alone. The majority of that demand is for ‘high-quality’ recycled polypropylene, APR has said.

Aptar is committed to reducing its impact on the planet while creating top quality, sustainable products and is working in partnership with several sustainability organizations to serve as a business thought leader and advocate for sustainable products and processes within the packaging industry. Today, Aptar has all-plastic solutions that are recyclable and has developed a line of closures, available in North America and Europe, made with post-consumer recycled resin. The company continues to explore additional opportunities for sustainable resins. Aptar is well positioned to help its customers achieve their own objectives, many of which are to achieve packaging that is 100% recyclable or reusable by 2025. For more information on Aptar’s sustainability efforts, please view the Corporate Sustainability Report on our website under Sustainability, or by clicking here.

Latest stories

Related stories

Pharmaceutical and Holistic Therapies: Exploring Their Role in Effective Addiction Recovery

Addiction recovery has evolved into a multidisciplinary clinical domain...

Driving Documentation Integrity Through Structured Drug Data

Establishing a robust framework for regulatory success requires moving beyond fragmented information silos toward a unified, digital-first approach. Comprehensive oversight of the pharmaceutical lifecycle depends on the ability to transform raw information into actionable insights, ensuring that every data point contributes to a larger narrative of safety and efficacy. By prioritizing specialized platforms that aggregate and organize complex information, organizations can achieve a level of transparency that satisfies the most stringent global standards while fostering a culture of continuous improvement.

Contamination Control with Toxicological Reference Data

Centralizing expert-verified toxicological datasets is now a critical requirement for modern pharmaceutical facilities operating under stringent global regulations. By transitioning from generic cleaning limits to precise Health-Based Exposure Limits derived from high-quality platforms, manufacturers ensure that cleaning validation protocols are scientifically sound and audit-ready. This approach integrates rigorous toxicological risk assessment into the broader contamination control strategy, safeguarding patient health while optimizing multi-product manufacturing efficiency and regulatory compliance.

Aligning Global Clinical Trials with Standardized Drug Data

Modern drug development necessitates a shift from fragmented data silos to a unified, intelligence-driven framework. Achieving global regulatory alignment requires a sophisticated approach to trial documentation standards and pharmaceutical regulatory governance, ensuring that clinical trial design remains robust across multiple jurisdictions. By leveraging standardized drug intelligence, sponsors can enhance submission readiness and maintain cross-border compliance, ultimately accelerating the delivery of life-saving therapies to patients worldwide.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »